Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

distal biliary tract carcinoma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

distal biliary tract carcinoma

MONDO:0003707

Also known as:carcinoma of distal biliary tractcarcinoma of the distal biliary tractdistal bile duct cancer

Find Clinical TrialsTrials

Overview

A carcinoma that arises from the common bile duct distal to the insertion of the cystic duct.

Treatments1 FDA approved

Clinical Trials4 registered · 1 recruiting

Diagnosis

Biomarker and diagnostic research for distal biliary tract carcinoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for distal biliary tract carcinoma, including PEMBROLIZUMAB (KEYTRUDA, approved 2014). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.

93 publications have been identified in PubMed for distal biliary tract carcinoma. Research spans Case Report / Case Series (31%), Review / Meta-Analysis (26%), and Diagnostic / Biomarker (16%).

Research Type	Count	% of Total
Patient case studies	29

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:31 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of KEYTRUDA for managing distal biliary tract carcinoma?
→Are any of the 4 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate (cis platinum PEG-pGlu) polymeric micelles	Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate (cis platinum PEG-pGlu) polymeric micelles	NanoCarrier Co., Ltd	2017	—	Designated

Kisho

distal biliary tract carcinoma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

distal biliary tract carcinoma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications